The Administrative Core provides the overall scientific leadership for the University of Colorado SPORE in Lung Cancer as well as providing outstanding administrative and fiscal support for the Program. The Administrative Core oversees all administrative and scientific activities of the SPORE Program;reviews and regulates financial expenditures;and prepares all reports. The Core consists of the SPORE Principal Investigator, Dr. Bunn, and the Co-PI, Dr. Miller;the SPORE Administrator, Michaela Montour;a finance specialist;and effort from the Cancer Center's grants manager, human resource manager, and operations manager for SPORE-related activities. These individuals provide a network of administrative and fiscal support to facilitate the scientific goals set by the leadership. In addition, the Administrative Core insures adherence to SPORE Guidelines, NIH policies, and other applicable federal, state and institutional policies. The Core works closely with institutional and Cancer Center leadership to insure the SPORE Program remains a priority at the institutional level;and it works closely with community advocates and fund raising groups to promote awareness of and support for the research conducted by the Program. The Core facilitates interactions with outside institutions including academic centers and industry. These interactions support visiting scientists and industry MTAs and contracts. The Core facilitates all planning and evaluation activities including the planning and support of the external and internal scientific advisory committees. The Core facilitates interactions with affiliated hospitals and medical centers including the VA Medical Center, the National Jewish Center, the University of Colorado Hospital, and institutions affiliated with the University of Colorado Comprehensive Cancer Center. Administratively, the Core performs fiscal management and oversight of the Program resources;facilitates planning and evaluation activities;schedules and staffs committees and other meetings related to the Program;exercises oversight of the other shared resource cores;disseminates information about national SPORE meetings and coordinates attendance;tracks publications by SPORE investigators;and facilitates the production of an annual progress report. The goal of these activities is the promotion of translational science that will facilitate interactions between basic and applied scientists to bring innovation to the clinic to reduce the burden of lung cancer.
The SPORE translational research program is large with multiple projects, multiple shared resource cores, and multiple collaborations and therefore administrative support is necessary. The Administrative Core provides scientific leadership and administrative experience to support its multi-year effort including fiscal support, planning, evaluation, and outreach support.
|Vaishnavi, Aria; Le, Anh T; Doebele, Robert C (2015) TRKing down an old oncogene in a new era of targeted therapy. Cancer Discov 5:25-34|
|Toschi, Luca; Finocchiaro, Giovanna; Nguyen, Teresa T et al. (2014) Increased SOX2 gene copy number is associated with FGFR1 and PIK3CA gene gain in non-small cell lung cancer and predicts improved survival in early stage disease. PLoS One 9:e95303|
|Marek, Lindsay A; Hinz, Trista K; von Mässenhausen, Anne et al. (2014) Nonamplified FGFR1 is a growth driver in malignant pleural mesothelioma. Mol Cancer Res 12:1460-9|
|Brosnan, Evelyn M; Weickhardt, Andrew J; Lu, Xian et al. (2014) Drug-induced reduction in estimated glomerular filtration rate in patients with ALK-positive non-small cell lung cancer treated with the ALK inhibitor crizotinib. Cancer 120:664-74|
|Wynes, Murry W; Hinz, Trista K; Gao, Dexiang et al. (2014) FGFR1 mRNA and protein expression, not gene copy number, predict FGFR TKI sensitivity across all lung cancer histologies. Clin Cancer Res 20:3299-309|
|Bunn Jr, Paul A; Hirsch, Fred R; Aisner, Dara L (2014) Is there clinical value to prognostic signatures in early-stage NSCLC? Clin Cancer Res 20:1727-9|
|Kim, Jihye; Vasu, Vihas T; Mishra, Rangnath et al. (2014) Bioinformatics-driven discovery of rational combination for overcoming EGFR-mutant lung cancer resistance to EGFR therapy. Bioinformatics 30:2393-8|
|Le, Anh T; Doebele, Robert C (2014) The democratization of the oncogene. Cancer Discov 4:870-2|
|Nakachi, Ichiro; Rice, Jessica L; Coldren, Christopher D et al. (2014) Application of SNP microarrays to the genome-wide analysis of chromosomal instability in premalignant airway lesions. Cancer Prev Res (Phila) 7:255-65|
|Shaw, Alice T; Ou, Sai-Hong I; Bang, Yung-Jue et al. (2014) Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med 371:1963-71|
Showing the most recent 10 out of 256 publications